Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 30, 2019Findings suggest potential efficacy for NRX-101 in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation following initial stabilization with ketamine.NeuroRx, a clinical stage biopharma company focused on development of drugs to target suicidal depression and PTSD, announced statistically significant final results from its Phase 2 STABIL-B...
-
December 13, 2018Findings suggest potential for NRX-101 in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation following initial stabilization with ketamine
WILMINGTON, Del. - NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Antidepressants (RAADs) that target the brain’s NMDA receptor, announced results from...
-
November 13, 2018First oral Rapid-Acting Antidepressant to be granted Breakthrough Designation
WILMINGTON, Del. - NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Antidepressants (RAADs) that target the brain’s NMDA receptor, has been granted...
-
September 5, 2018
WILMINGTON, Del., Sept. 05, 2018 -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior...
-
September 4, 2018
WILMINGTON, De. , Sept. 04, 2018 -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior...
Click here to view our corporate presentation or on the image below
 |
